Measuring Levels of SMN in Blood Samples of SMA Patients
Study Details
- All Spinal Muscular Atrophies
- Diagnosis of SMA with genetically proven mutations in the SMN1 gene or unaffected family members (age greater than or equal to 2 years).
- No exposure to valproic acid or any other HDAC inhibitors for a period of at least 2 weeks.
- Written, informed consent (and assent, if applicable).
- History of valproic acid or other HDAC inhibitor use within the past14 days.
- History of bleeding disorder, which would make a blood draw unsafe.
Protocol Summary
Spinal muscular atrophy (SMA) is a disorder that affects the motor neurons. SMA is caused by a mutation in a part of the DNA called the survival motor neuron (SMN1) gene, which normally produces a protein called SMN. Because of their gene mutation, people with SMA make less SMN protein, which results in the loss of motor neurons. SMA symptoms may be improved by increasing the levels of SMN protein. The purpose of this study is to determine whether a drug called a histone deacetylase inhibitor can increase SMN levels.
After undergoing a general medical and neurological evaluation, study participants will donate a blood sample. Researchers will use this sample to measure SMN levels. They will also isolate cells from the blood and treat the cells with various drugs that may increase SMN levels.
Trial Locations
Contact Cure SMA
User Information
If you have general questions regarding clinical trials or would like to be added to the Cure SMA mailing list to receive communications regarding future registries, studies, or clinical trials in SMA, please fill out the form below. Fields marked with an asterisk (*) are mandatory.